Navarro M et al., 2020-04: Systematic review and meta-analysis of trials giving ivermectin at 200 mcg/kg and above, including 400 mcg/kg and higher. It found no difference in adverse-event incidence by severity between standard and higher doses, apart from more transient ocular events at the higher dose in one onchocerciasis trial, but concluded the data are insufficient to recommend higher-than-approved dosing.
Although within this review the safety of high-dose ivermectin appears to be comparable to standard doses, there are not enough data to support a recommendation for its use in higher-than-approved doses.
Navarro M et al., 2020-04: Systematic review and meta-analysis of trials giving ivermectin at 200 mcg/kg and above, including 400 mcg/kg and higher. It found no difference in adverse-event incidence by severity between standard and higher doses, apart from more transient ocular events at the higher dose in one onchocerciasis trial, but concluded the data are insufficient to recommend higher-than-approved dosing. C2 systematic review. Study type: systematic review and meta-analysis; six clinical trials included for the meta-analysis (doses >=200 and >=400 mcg/kg); countries of included trials not enumerated in the abstract captured; multinational author group (Spain, Italy, Cameroon). Doses: standard up to 400 mcg/kg vs higher regimens, oral. Funder: not stated in the PubMed record; no grants listed. Declared conflicts: none recorded in the PubMed record. Comparator: standard-dose arms. Bearing is PARTLY SUPPORTS because the same review states there are not enough data to support higher-than-approved doses, while finding no excess of adverse events. The one signal it reports is ocular events in a higher-dose onchocerciasis trial, transient and mild to moderate. Study type: review.
